Effects of statins on cancer mortality and progression: A systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals

International Journal of Cancer

Volumn 140, Issue 5, 2017, Pages 1068-1081

  Mei, Zubing ^a   Liang, Mining ^b,c   Li, Lezhi ^b,c   Zhang, Yi ^d   Wang, Qingming ^a   Yang, Wei ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d Department of Plastic and Reconstructive Surgery The First People's Hospital of Jiashan   (China)

Author keywords

cancer; meta analysis; mortality; progression; recurrence; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; BILIARY TRACT CANCER; BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG USE; ESOPHAGUS CANCER; FOLLOW UP; GLIOBLASTOMA; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASM; MELANOMA; META ANALYSIS; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RECURRENCE FREE SURVIVAL; STOMACH CANCER; SYSTEMATIC REVIEW; UTERUS CANCER; CAUSE OF DEATH; DISEASE COURSE; DISEASE PREDISPOSITION; MORTALITY; MULTICENTER STUDY (TOPIC); NEOPLASM; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TRENDS;

CAUSE OF DEATH; COHORT STUDIES; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; DISEASE-FREE SURVIVAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MORTALITY; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 85010417614     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30526     Document Type: Article

References (129)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.
2. Chalkidou K, Marquez P, Dhillon PK, et al. Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries. Lancet Oncol 2014;15:e119–31.
3. Ali R, Finlayson A, Network ICR. Building capacity for clinical research in developing countries: the INDOX Cancer Research Network experience. Global Health Action 2012;5. doi:10.3402/gha.v5i0.17288.
4. Pisanti S, Picardi P, Ciaglia E, et al. Novel prospects of statins as therapeutic agents in cancer. Pharmacol Res 2014;88:84–98.
5. Miraglia E, Högberg J, Stenius U. Statins exhibit anticancer effects through modifications of the pAkt signaling pathway. Int J Oncol 2012;40:867–75.
6. Osmak M. Statins and cancer: current and future prospects. Cancer Lett 2012;324:1–12.
7. Sendur MA, Aksoy S, Yazici O, et al. Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer. Med Oncol 2014;31:835.
8. Oh DS, Koontz B, Freedland SJ, et al. Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy. World J Urol 2015;33:93–97.
9. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792–802.
10. Murtola T, Maattanen L, Taari K, et al. Statin use and survival after prostate cancer diagnosis in the finnish prostate cancer screening trial. J Urol 2014;191:e832
11. Marcella SW, David A, Ohman-Strickland PA, et al. Statin use and fatal prostate cancer: a matched case-control study. Cancer 2012;118:4046–52.
12. Lavie O, Pinchev M, Rennert HS, et al. The effect of statins on risk and survival of gynecological malignancies. Gynecol Oncol 2013;130:615–19.
13. Kollmeier MA, Katz MS, Mak K, et al. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2011;79:713–18.
14. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001;84:886–91.
15. Katz MS, Carroll PR, Cowan JE, et al. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int 2010;106:627–32.
16. Hamilton RJ, Banez LL, Aronson WJ, et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010;116:3389–98.
17. Elmore RG, Ioffe Y, Scoles DR, et al. Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol Oncol 2008;111:102–5.
18. Allott EH, Howard LE, Cooperberg MR, et al. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 2014.
19. Ahern TP, Pedersen L, Tarp M, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 2011;103:1461–8.
20. Da Silva FC, Jr, De Silva FC, Goncnullalves F, et al. Effects of prior use of statins in a phase 3 study of intermittent versus continuous combined androgen deprivation. J Urol 2014;191:e768.
21. Cheema F, Abraham NS, Hartman C, et al. Mortality and adherence to statin and anti-hypertensive medicines in older colorectal cancer patients with diabetes. J Am Geriatr Soc 2010;58:S224.
22. Grytli HH, Fagerland MW, Fosså SD, et al. Association between use of β-blockers and prostate cancer–specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 2014;65:635–41.
23. Moyad MA, Merrick GS, Butler WM, et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005;66:1150–4.
24. Livingstone E, Hollestein LM, Herk-Sukel MP, et al. Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort study. Cancer Med 2014;3:1284–93.
25. Hamadani M, Hade E, Benson DM, Jr, et al. The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma. Biol Blood Marrow Transplant 2008;14:351–2.
26. Segal R, Yafi FA, Brimo F, et al. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int 2012;109:1026–30.
27. Yoon LS, Goodman MT, Rimel B, et al. Statin use and survival in elderly patients with endometrial cancer. Gynecol Oncol 2015;137:252–7.
28. Geybels MS, Wright JL, Holt SK, et al. Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. Prostate 2013;73:1214–22.
29. Ishak-Howard MB, Okoth LA, Cooney KA. Statin use and the risk of recurrence after radical prostatectomy in a cohort of men with inherited and/or early-onset forms of prostate cancer. Urology 2014;83:1356–61.
30. Crivelli JJ, Xylinas E, Kluth LA, et al. Effect of statin use on outcomes of non-muscle-invasive bladder cancer. BJU Int 2013;112:E4−12.
31. Da Silva RD, Xylinas E, Kluth L, et al. Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Urol 2013;190:487–92.
32. Hamilton R, Vijai J, Gallagher D, et al. Analysis of statin medication, genetic variation and prostate cancer outcomes. J Urol 2011;185:e401
33. Mondul AM, Han M, Humphreys EB, et al. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J Urol 2011;185:1268–73.
34. Niraula S, Pond G, de Wit R, et al. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J 2013;7:E74–81.
35. Viers B, Thompson RH, Psutka S, et al. The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. J Urol 2015;193:e871
36. Gayed B, Meissner M, Konijeti R, et al. Statin use is an independent predictor of improved survival in patients with metastatic renal cell carcinoma. J Urol 2014;191:e641.
37. Lipworth L, Fazio S, Kabagambe EK, et al. A prospective study of statin use and mortality among 67,385 blacks and whites in the Southeastern United States. Clin Epidemiol 2014;6:15–25.
38. Cardwell CR, Mc Menamin U, Hughes CM, et al. Statin use and survival from lung cancer: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 2015;24:833–41.
39. Cardwell CR, Hicks BM, Hughes C, et al. Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol 2014;32:3177–83.
40. Cardwell CR, Hicks BM, Hughes C, et al. Statin use after diagnosis of breast cancer and survival: a population-based cohort study. Epidemiology 2014;26:68–78.
41. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74–80.
42. Ahern TP, Lash TL, Damkier P, et al. Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol 2014;15:e461–8.
43. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
44. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
45. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815–34.
46. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
47. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–1558.
48. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. Systematic reviews in health care: meta-analysis in context, 2nd edn., 2008. 285–312.
49. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.
50. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
51. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–63.
52. Song C, Park S, Park J, et al. Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer. Prostate 2015;75:211–217.
53. Shao YY, Hsu CH, Yeh KH, et al. Statin use is associated with improved prognosis of colorectal cancer in Taiwan. Clin Colorectal Cancer 2015;14:177–184.e4.
54. Kaffenberger SD, Lin-Tsai O, Stratton KL, et al. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urol Oncol 2015;14:177–184.e4.
55. Jeon CY, Pandol SJ, Wu B, et al. The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-Medicare analysis. PLoS One 2015;10:e0121783.
56. Hoffmeister M, Jansen L, Rudolph A, et al. Statin use and survival after colorectal cancer: the importance of comprehensive confounder adjustment. J Natl Cancer Inst 2015;107:djv045.
57. Feng CH, Miller CM, Salgia MM, et al. Statin use significantly improves overall survival in high-grade endometrial cancer. Gynecol Oncol 2015;137:36.
58. Desai P, Lehman A, Chlebowski RT, et al. Statins and breast cancer stage and mortality in the Womennulls Health Initiative. Cancer Causes Control 2015;26:529–39.
59. Cuaron J, Pei X, Cohen GN, et al. Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer. Brachytherapy 2015;14:179–84.
60. Cattarino S, Seisen T, Drouin SJ, et al. Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: a single center study. Can J Urol 2015;22:7703–8.
61. Yu O, Eberg M, Benayoun S, et al. Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol 2014;32:5–11.
62. Nam DH, Lee H, Park JC, et al. Long-term statin therapy improves oncological outcome after radical gastrectomy for stage II and III gastric cancer. Anticancer Res 2014;34:355–361.
63. McNamara MG, Aneja P, Le LW, et al. Effects of statin, aspirin, or metformin use on recurrence free and overall survival in patients with biliary tract cancer (BTC). J Clin Oncol 2014;32(Suppl. 3)[abstract 303].
64. Hamilton RJ, Morilla D, Cabrera F, et al. The association between statin medication and progression after surgery for localized renal cell carcinoma. J Urol 2014;191:914–9.
65. Habis M, Wroblewski K, Bradaric M, et al. Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. PLoS One 2014;9:e104521.
66. Gaist D, Hallas J, Friis S, et al. Statin use and survival following glioblastoma multiforme. Cancer Epidemiol 2014;38:722–7.
67. Dehlendorff C, Skriver C, Jespersen CG, et al. Use of statins and prostate cancer mortality. Pharmacoepidemiol Drug Saf 2014;23:354.
68. Caon J, Paquette M, Hamm J, et al. Does statin or ASA affect survival when prostate cancer is treated with external beam radiation therapy? Prostate Cancer 2014;2014:184297.
69. Boudreau DM, Yu O, Chubak J, et al. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat 2014;144:405–16.
70. Ampuero J, Calle R, Figueruela B, et al. Statins and metformin use improve prognosis after diagnosis of hepatocelullar carcinoma. Hepatology 2014;60:877A.
71. Abdel-Wahab R, Hassabo HM, El Antably A, et al. Prognostic effect of statins on hepatocellular carcinoma in presence and absence of metformin intake. Hepatology 2014;60:832A.
72. Yun Yu OH, Yin H, Benayoun S, et al. Post-diagnostic use of statins and the prevention of mortality and metastasis in patients with prostate cancer: nested case-control study. Pharmacoepidemiol Drug Saf 2013;22:354.
73. Spoozak LA, Girda E, Van Arsdale A, et al. Statin use in uterine malignancies. J Clin Oncol 2013;31 (suppl; abstract 5592).
74. Rieken M, Kluth LA, Xylinas E, et al. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. Prostate Cancer Prostatic Dis 2013;16:367–71.
75. Nickels S, Vrieling A, Seibold P, et al. Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohort. PLoS One 2013;8:e75088.
76. Nevadunsky NS, Van Arsdale A, Spoozak L, et al. Hyperlipidemia and statin use is associated with improved endometrial cancer survival. Reproductive Sci 2013;20:340A.
77. Murtola TJ, Visvanathan K, Artama M, et al. Breast cancer mortality among users of cholesterol-lowering drugs. J Clin Oncol 2013;31:1514.
78. Mace AG, Gantt GA, Skacel M, et al. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer. Dis Colon Rectum 2013;56:1217–27.
79. Ma WL, Shao YY, Hsu CH, et al. Regular statin users and colorectal cancer (CRC) prognosis. J Clin Oncol 2013;31:3554.
80. Choi SK, Min GE, Jeon SH, et al. Effects of statins on the prognosis of local and locally advanced renal cell carcinoma following nephrectomy. Mol Clin Oncol 2013;1:365–8.
81. Chavez-Mac Gregor M, Lei X, Litton JK, et al. Statin use and outcome among breast cancer patients treated with neoadjuvant systemic chemotherapy. Cancer Res 2013;73:P3–12.
82. Chao C, Jacobsen SJ, Xu L, et al. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy. BJU Int 2013;111:954–62.
83. Chae YK, Kaseb AO, Mohamed H, et al. The association between statin use and hepatocellular cancer outcome. J Clin Oncol 2013;31:165.
84. Brewer TM, Masuda H, Liu DD, et al. Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer 2013;109:318–24.
85. Amsler ME, Chmiel KA, Yaremko O, et al. Statins use prevents ovarian cancer recurrence in women with diabetes mellitus. Cancer Res 2013;73(8 Suppl):Abstract nr LB-18.
86. Alexandre L, Clark A, Bhutta H, et al. Statin use is associated with improved survival in patients with oesophageal cancer: a survival analysis using the UK general practice research database and national cancer registry. Gut 2013;62:A12–3.
87. Ramakrishna S, Andrei AC, Varlotto J, et al. Statin use is associated with decreased local recurrence and improved overall survival in resectable non-small cell lung cancer (NSCLC). Chest 2012;142:925A–925A.
88. Misrai V, Do C, Lhez JM, et al. Is statin use associated with D'Amico risk groups and biochemical recurrence after radical prostatectomy? Prog Urol 2012;22:273–8.
89. Lakha F, Theodoratou E, Farrington SM, et al. Statin use and association with colorectal cancer survival and risk: case control study with prescription data linkage. BMC Cancer 2012;12:1.
90. Lacerda L, Reddy J, Liu D, et al. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with post-mastectomy radiation. Cancer Res 2012;72:Abstract nr PD03-06.
91. King GT, Yun JH, Chae YK, et al. Statin use and the development of bone metastasis in breast cancer patients. J Clin Oncol 2012;30:40.
92. Haukka J, Niskanen L, Partonen T, et al. Statin usage and all-cause and disease-specific mortality in a nationwide study. Pharmacoepidemiol Drug Saf 2012;21:61–9.
93. Ritch CR, Hruby G, Badani KK, et al. Effect of statin use on biochemical outcome following radical prostatectomy. BJU Int 2011;108:E211–6.
94. Ng K, Ogino S, Meyerhardt JA, et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst 2011;103:1540–51.
95. Mozayen M, Omaira M, Kanaan M, et al. The effect of statins on overall survival of breast cancer. J Clin Oncol 2011;29:34.
96. Leigh D, Eken J, Beal JR, et al. Statins use and risk for brain metastasis from lung cancer. Cancer Invest 2011;29:68–72.
97. Ku JH, Jeong CW, Park YH, et al. Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis 2011;14:63–8.
98. Ishak M, Cooney K. The association between statin use and risk of biochemical recurrence in men treated with radical prostatectomy in a cohort of men with inherited forms of prostate cancer. Cancer Res 2011;71:5569–5569.
99. Chagpar RB, Martin RC, Ahmad SA, et al. Medically managed hypercholesterolemia and insulin-dependent diabetes mellitus preoperatively predicts poor survival after surgery for pancreatic cancer. J Gastrointest Surg 2011;15:551–7.
100. Chae YK, Valsecchi ME, Kim J, et al. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 2011;29:585–93.
101. Ceacareanu AC, Hong C, Brennan JJ, et al. Statin treatment use in diabetic patients with breast cancer: a potential C-reactive protein mediated benefit. J Clin Oncol 2011;29:173.
102. Shanafelt TD, Rabe KG, Kay NE, et al. Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:1233–40.
103. Gutt R, Tonlaar N, Kunnavakkam R, et al. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010;28:2653–9.
104. Van Gestel YRBM, Hoeks SE, Sin DD, et al. COPD and cancer mortality: the influence of statins. Thorax 2009;64:963–7.
105. Soto DE, Daignault S, Sandler HM, et al. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 2009;73:158–62.
106. Siddiqui AA, Nazario H, Mahgoub A, et al. For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig Dis Sci 2009;54:1307–11.
107. Ciminello L, Toomey CE, Abramson JS, et al. Statins may prolong survival in relapsed DLBCL by upregulating p27: a retrospective case-control study. Blood 2009;114:1380–1380.
108. Ciminello L, Toomey C, Cobert J, et al. Statin use improves overall survival and time to treatment failure in patients with primary CNS lymphoma. Blood 2009;114:2496–2496.
109. Kwan ML, Habel LA, Flick ED, et al. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 2008;109:573–9.
110. Hamadani M, Awan FT, Devine SM. The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Blood 2008;111:X3901–2.
111. Tsai HK, Katz MS, Coen JJ, et al. Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer. Urology 2006;68:1188–92.
112. Moyad MA, Merrick GS, Butler WM, et al. Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs 2006;26:298–303.
113. Demierre MF, Higgins PD, Gruber SB, et al. Statins and cancer prevention. Nat Rev Cancer 2005;5:930–942.
114. Fenton RG, Kung HF, Longo DL, et al. Regulation of intracellular actin polymerization by prenylated cellular proteins. J Cell Biol 1992;117:347–56.
115. Herold G, Jungwirth R, Rogler G, et al. Influence of cholesterol supply on cell growth and differentiation in cultured enterocytes (CaCo-2). Digestion 1995;56:57–66.
116. Kodach LL, Bleuming SA, Peppelenbosch MP, et al. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. Gastroenterology 2007;133:1272–81.
117. Thurnher M, Gruenbacher G, Nussbaumer O. Regulation of mevalonate metabolism in cancer and immune cells. Biochim Biophys Acta 2013;1831:1009–15.
118. Borgquist S, Jogi A, Ponten F, et al. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. Breast Cancer Res 2008;10:R79.
119. Zhong S, Zhang X, Chen L, et al. Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies. Cancer Treat Rev 2015;41:554–567.
120. Cai H, Zhang G, Wang Z, et al. Relationship between the use of statins and patient survival in colorectal cancer: a systematic review and meta-analysis. PloS One 2015;10:e0126944.
121. Ling Y, Yang L, Huang H, et al. Prognostic significance of statin use in colorectal cancer: a systematic review and meta-analysis. Medicine 2015;94.
122. Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144:427–37.
123. Alexandre L, Clark AB, Bhutta HY, et al. Association between statin use after diagnosis of esophageal cancer and survival: a population-based cohort study. Gastroenterology 2016;150:854–65.
124. McAuley L, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet 2000;356:1228–31.
125. Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013;346:f2610
126. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderatedose statin therapy: a meta-analysis. JAMA 2011;305:2556–64.
127. Galtier F, Mura T, Raynaud de Mauverger E, et al. Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers. Toxicol Appl Pharmacol 2012;263:281–6.
128. Paiva H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005;78:60–68.
129. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781–1790.